EFFECT OF BONE-MARROW TRANSPLANTATION ON ANTIPHOSPHOLIPID ANTIBODY SYNDROME IN MURINE LUPUS MICE

被引:43
作者
ADACHI, Y
INABA, M
AMOH, Y
YOSHIFUSA, H
NAKAMURA, Y
SUZUKA, H
AKAMATU, S
NAKAI, S
HARUNA, H
ADACHI, M
GENBA, H
IKEHARA, S
机构
[1] NATL CARDIOVASC CTR,DEPT PEDIAT,SUITA,OSAKA 565,JAPAN
[2] KANSAI MED UNIV,DEPT PHYSIOL 2,MORIGUCHI,OSAKA 570,JAPAN
[3] NIPPON SHINYAKU CO LTD,KYOTO,JAPAN
[4] OTSUKA PHARMACEUT CO LTD,TOKUSHIMA 77101,JAPAN
关键词
D O I
10.1016/S0171-2985(11)80099-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The (NZW x BXSB)F1 (W/BF1) mouse is known to be an animal model of systemic lupus erythematosus (SLE) and immune thrombocytopenic purpura (ITP). These mice produce not only anti-DNA antibodies bur also anti-platelet antibodies, resulting in decreased platelet counts. They show a high level of proteinuria, increased white blood cell (WBC) counts, hypertension, and myocardial infarction due to the high levels of anti-cardiolipin antibodies. When W/BF1 mice (4-5 months) were lethally irradiated and then reconstituted with T cell-depleted bone marrow cells of normal BALB/c mice (8 weeks), 60 % of the mice survived more than one year. The WBC and platelet counts in the mice were normalized, and the levels of anti-DNA and anti-platelet antibodies decreased. The renal dysfunction was also ameliorated as indicated by a lower level of proteinuria, lower levels of serum creatinine (S-CRTN) and blood urea nitrogen (BUN), and by improved histology. The blood pressure (BP) of the treated W/BF1 mice decreased due to the improved renal functions. In contrast to the non-treated W/BF1 mice which died of myocardial infarction or renal failure by the age of 7 months, the treated W/BF1 mice showed no evidence of myocardial infarction even one year after BMT. This was due to the lower cardiolipin levels.
引用
收藏
页码:218 / 230
页数:13
相关论文
共 22 条
[1]   ANTICARDIOLIPIN ANTIBODIES (IGG AND IGA) IN WOMEN WITH RECURRENT FETAL LOSS CORRELATE TO CLINICAL AND SEROLOGICAL CHARACTERISTICS OF SLE [J].
BAGGER, PV ;
ANDERSEN, V ;
BASLUND, B ;
BECK, B ;
HOVE, H ;
HOIERMADSEN, M ;
PETERSEN, J ;
PHILIP, J ;
SCHAADT, O ;
SKOUBY, SO ;
STARUP, J ;
THORSEN, S ;
WIIK, A .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1993, 72 (06) :465-469
[2]   THE ROLE OF HYPERTENSION IN THE VASCULAR-DISEASE AND MYOCARDIAL INFARCTS ASSOCIATED WITH MURINE SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
HANG, L ;
STEPHENSLARSON, P ;
HENRY, JP ;
DIXON, FJ .
ARTHRITIS AND RHEUMATISM, 1983, 26 (11) :1340-1345
[3]   (NZW X BXSB)F1 HYBRID - A MODEL OF ACUTE LUPUS AND CORONARY VASCULAR-DISEASE WITH MYOCARDIAL-INFARCTION [J].
HANG, LM ;
IZUI, S ;
DIXON, FJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 154 (01) :216-221
[4]  
HASHIMOTO Y, 1992, J IMMUNOL, V149, P1063
[5]   MODEL OF PSYCHOSOCIAL HYPERTENSION SHOWING REVERSIBILITY AND PROGRESSION OF CARDIOVASCULAR COMPLICATIONS [J].
HENRY, JP ;
STEPHENS, PM ;
SANTISTEBAN, GA .
CIRCULATION RESEARCH, 1975, 36 (01) :156-164
[6]  
ICHIKAWA K, 1988, CLIN EXP IMMUNOL, V74, P110
[7]   RATIONALE FOR BONE-MARROW TRANSPLANTATION IN THE TREATMENT OF AUTOIMMUNE-DISEASES [J].
IKEHARA, S ;
GOOD, RA ;
NAKAMURA, T ;
SEKITA, K ;
INOUE, S ;
OO, MM ;
MUSO, E ;
OGAWA, K ;
HAMASHIMA, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (08) :2483-2487
[8]   LONG-TERM OBSERVATIONS OF AUTOIMMUNE-PRONE MICE TREATED FOR AUTOIMMUNE-DISEASE BY ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
IKEHARA, S ;
YASUMIZU, R ;
INABA, M ;
IZUI, S ;
HAYAKAWA, K ;
SEKITA, KI ;
TOKI, J ;
SUGIURA, K ;
IWAI, H ;
NAKAMURA, T ;
MUSO, E ;
HAMASHIMA, Y ;
GOOD, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (09) :3306-3310
[9]   PREVENTION OF TYPE-I DIABETES IN NONOBESE DIABETIC MICE BY ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
IKEHARA, S ;
OHTSUKI, H ;
GOOD, RA ;
ASAMOTO, H ;
NAKAMURA, T ;
SEKITA, K ;
MUSO, E ;
TOCHINO, Y ;
IDA, T ;
KUZUYA, H ;
IMURA, H ;
HAMASHIMA, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (22) :7743-7747
[10]  
IKEHARA S, 1991, CULA S MOL CELLULAR, V137, P251